346 related articles for article (PubMed ID: 33262523)
1. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.
Croft J; Ellis S; Sherborne AL; Sharp K; Price A; Jenner MW; Drayson MT; Owen RG; Chown S; Lindsay J; Karunanithi K; Hunter H; Gregory WM; Davies FE; Morgan GJ; Cook G; Atanesyan L; Savola S; Cairns DA; Jackson G; Houlston RS; Kaiser MF
Leukemia; 2021 Jul; 35(7):2043-2053. PubMed ID: 33262523
[TBL] [Abstract][Full Text] [Related]
2. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah V; Sherborne AL; Walker BA; Johnson DC; Boyle EM; Ellis S; Begum DB; Proszek PZ; Jones JR; Pawlyn C; Savola S; Jenner MW; Drayson MT; Owen RG; Houlston RS; Cairns DA; Gregory WM; Cook G; Davies FE; Jackson GH; Morgan GJ; Kaiser MF
Leukemia; 2018 Jan; 32(1):102-110. PubMed ID: 28584253
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Panopoulou A; Cairns DA; Holroyd A; Nichols I; Cray N; Pawlyn C; Cook G; Drayson M; Boyd K; Davies FE; Jenner M; Morgan GJ; Owen R; Houlston R; Jackson G; Kaiser MF
Blood; 2023 Apr; 141(14):1666-1674. PubMed ID: 36564045
[TBL] [Abstract][Full Text] [Related]
4. High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma.
Kosztolányi S; Kiss R; Atanesyan L; Gángó A; de Groot K; Steenkamer M; Jáksó P; Matolcsy A; Kajtár B; Pajor L; Szuhai K; Savola S; Bödör C; Alpár D
J Mol Diagn; 2018 Nov; 20(6):777-788. PubMed ID: 30096382
[TBL] [Abstract][Full Text] [Related]
5. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
Lannes R; Samur M; Perrot A; Mazzotti C; Divoux M; Cazaubiel T; Leleu X; Schavgoulidze A; Chretien ML; Manier S; Adiko D; Orsini-Piocelle F; Lifermann F; Brechignac S; Gastaud L; Bouscary D; Macro M; Cleynen A; Mohty M; Munshi N; Corre J; Avet-Loiseau H
J Clin Oncol; 2023 Mar; 41(9):1695-1702. PubMed ID: 36343306
[TBL] [Abstract][Full Text] [Related]
6. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J; Goyal S; Chen Z; Boise LH; Lonial S; Nooka AK; Kaufman JL
Blood Cancer J; 2019 Nov; 9(12):94. PubMed ID: 31767829
[TBL] [Abstract][Full Text] [Related]
7. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Jones JR; Weinhold N; Ashby C; Walker BA; Wardell C; Pawlyn C; Rasche L; Melchor L; Cairns DA; Gregory WM; Johnson D; Begum DB; Ellis S; Sherborne AL; Cook G; Kaiser MF; Drayson MT; Owen RG; Jackson GH; Davies FE; Greaves M; Morgan GJ;
Haematologica; 2019 Jul; 104(7):1440-1450. PubMed ID: 30733268
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
9. The shaping and functional consequences of the dosage effect landscape in multiple myeloma.
Samur MK; Shah PK; Wang X; Minvielle S; Magrangeas F; Avet-Loiseau H; Munshi NC; Li C
BMC Genomics; 2013 Oct; 14():672. PubMed ID: 24088394
[TBL] [Abstract][Full Text] [Related]
10. Deciphering the chronology of copy number alterations in Multiple Myeloma.
Aktas Samur A; Minvielle S; Shammas M; Fulciniti M; Magrangeas F; Richardson PG; Moreau P; Attal M; Anderson KC; Parmigiani G; Avet-Loiseau H; Munshi NC; Samur MK
Blood Cancer J; 2019 Mar; 9(4):39. PubMed ID: 30914633
[TBL] [Abstract][Full Text] [Related]
11. Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
Cui J; Lv R; Yu T; Yan W; Xu J; Fan H; Li L; Liu Y; Du C; Deng S; Sui W; Xu Y; Yi S; Zou D; Qiu L; An G
Haematologica; 2024 Feb; 109(2):591-603. PubMed ID: 37534514
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Allotey D; Shafeek S; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Clinical Studies Group UNHO
Haematologica; 2021 Jul; 106(7):1957-1967. PubMed ID: 32499244
[TBL] [Abstract][Full Text] [Related]
13. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Samur MK; Roncador M; Aktas Samur A; Fulciniti M; Bazarbachi AH; Szalat R; Shammas MA; Sperling AS; Richardson PG; Magrangeas F; Minvielle S; Perrot A; Corre J; Moreau P; Thakurta A; Parmigiani G; Anderson KC; Avet-Loiseau H; Munshi NC
Blood; 2023 Apr; 141(14):1724-1736. PubMed ID: 36603186
[TBL] [Abstract][Full Text] [Related]
14. The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of patients with multiple myeloma.
Salomon-Perzyński A; Bluszcz A; Krzywdzińska A; Spyra-Górny Z; Jakacka N; Barankiewicz J; Borg K; Solarska I; Szpila T; Puła B; Grosicki S; Jamroziak K
Pol Arch Intern Med; 2020 Jun; 130(6):483-491. PubMed ID: 32338840
[TBL] [Abstract][Full Text] [Related]
15. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
[TBL] [Abstract][Full Text] [Related]
16. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Hockaday A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ;
Lancet Oncol; 2019 Jan; 20(1):57-73. PubMed ID: 30559051
[TBL] [Abstract][Full Text] [Related]
18. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Molecular Cancer Cell Line Characterization Using Digital Multiplex Ligation-Dependent Probe Amplification for Improved Standardization of in Vitro Research.
Menezes K; Atanesyan L; Sherborne AL; Steenkamer M; Clemens I; Savola S; Kaiser MF
J Mol Diagn; 2020 Sep; 22(9):1179-1188. PubMed ID: 32603764
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.
Krzeminski P; Corchete LA; García JL; López-Corral L; Fermiñán E; García EM; Martín AA; Hernández-Rivas JM; García-Sanz R; San Miguel JF; Gutiérrez NC
Oncotarget; 2016 Dec; 7(49):80664-80679. PubMed ID: 27811368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
